NCT02773004View on ClinicalTrials.gov

Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer

NACompletedINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

December 31, 2017

Conditions
Breast Cancer
Interventions
OTHER

EPClin genomic test

Sponsors

Collaborators (1)

Myriad Genetics, Inc.
All Listed Sponsors
collaborator

Myriad Genetics, Inc.

INDUSTRY

lead

UNICANCER

OTHER

NCT02773004 - Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer | Biotech Hunter | Biotech Hunter